Quote:

---

So because of this thinking, I am led to believe that NSF may decide to forego a future trial if a settlement would be offered them. They may see all this evidence, as presented to them by Sidley Austin, all building up against them, and even agree with it all. If the FDA GCP Audit is favorable for CytoDyn, this is hardline for NSF to make hair stand up on their back. In addition, they may even be made aware or privy to the collusive efforts of Amarex with 13D and big pharma and they just might see the writing on the wall presented to them by Sidley Austin.

Bottom line, my thinking, NSF may decide to forego the attorney expense of a future trial and just settle.

---